Life is a difficult challenge for Mr Bean, who despite being a grown adult, has trouble completing even the simplest of tasks. Thankfully, his perseverence is usually rewarded, and he finds an ingenious way around the problem.
Definitely no big additional news, but a few tid-bits. Stage 1 of Enchant-1 has 15 patients. The HER+ arm is not yet at 15 but still recruiting. The TNBC arm has now recruited the full 15. They will move onto stage 2 to recruit an additional 18 patients for a total of 33 in each arm. SNTA should be able to present the Enchant-1 data at ESMO this year. The Ganetespib + paclitaxel arm will be a follow up to those receiving Ganetespib only. The plan for breast cancer is combination studies, and a number of investigator sponsor initiated trial are in progress or planned. The breast cancer program will focus on TNBC followed by HER+. SNTA emphasized the effectiveness of Ganetespib in inhibiting the formation of new lesions.
I was listening to the call until it was abruptly cut off when an analyst was asking about the one patient who got a complete response. It sounded like they were asking if the patient had received any prior chemo before giving the drug. Can anyone tell me what they said about this patient. Probably not good since it has tanked since I was cutoof from the remainder of the Conf call.